Fasoracetam for ADHD

Fasoracetam (NFC-1, AEVI-001) is a racetame.
Fasoracetam is a non-stimulatory modulator (agonist) of all 3 groups of metabotropic glutamate receptors.
Fasoracetam is bioavailable when taken orally and is excreted largely unchanged in the urine.

In rodent studies, it improved cognitive function.
Fasoracetam was unsuccessful in phase 3 trials for the treatment of vascular dementia. Studies in primates and rodents found no evidence of dependence or addiction.¹

Fasoracetam may be effective in treating ADHD in sufferers with certain mGluR mutations. This is about 10% of all ADHD cases. In all other cases, fasoracetam is likely to be ineffective.
A 5-week, open-label, single-blind, placebo-controlled, registered trial in 30 adolescents 12-17 years of age with ADHD and mutations in mGluR network genes showed significant improvement in ADHD symptoms without increased side effects.²
Two other registered studies found no improvements in ADHD symptoms in sufferers without and with glutamate receptor gene mutations.³